Patients & Caregivers
Approval of Stutent Expanded to Reduce Carcinoma Recurrence
Stutent (sunitinib malate), which was developed by Pfizer and originally approved by the FDA in 2006 for gastrointestinal stromal tumors, received an approval expansion today.
FDA Gives Go-Ahead to Obinutuzumab for Follicular Lymphoma Treatment
On the same day that Genentech received U.S. FDA approval for emicizumab, the regulatory agency has also given the green light to Gazyva to treat follicular lymphoma.
FDA Approves Hemlibra to Treat Bleeding in Hemophilia A Patients
The U.S. Food and Drug Administration (FDA) approved Genentech’s Hemlibra for patients with hemophilia A who have developed Factor VIII inhibiting antibodies.
John Gordan of UCSF Discusses His Work in Fibrolamellar Carcinoma
John Gordan of UCSF discusses his experience in fibrolamellar, and what he’s been seeing with his most recent research.
New Data Shows Positive Effects of BLU-285 in Gastrointestinal Tumors
New Phase 1 clinical data for BLU-285 supports previous data that demonstrated the drug as exhibiting strong clinical activity and an encouraging safety profile.
Sprycel Approval Expanded to Include Treatment of Children with Rare Chronic Myeloid Leukemia Variation
Bristol-Myers Squibb announced that the FDA has expanded its approval of Sprycel tablets. The new indication includes children with rare chronic myeloid leukemia.
FDA Approves Adcetris for Rare Skin Cancers
Adcetris (brentuximab vedotin) approved to treat 2 rare skin cancer: pcALCL and CD30 positive MF
Ghassan Abou-Alfa, MD Discusses Fibrolamellar Cancer
Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center in New York City, specializes in gastrointestinal cancers.
Being Afraid to Dream: Life with Chemotherapy-Induced Hearing Loss
Everybody else is figuring out what they want to do for a job, school, vacations. And I'm barely getting through every single day.
A Parent's Silent Prayer: Preventing Hearing Loss for Childhood Cancer Survivors
While hearing loss is just 1 of multiple side effects that many risk cancer survivors experience, this loss touches almost every aspect of one’s life.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.